Related references
Note: Only part of the references are listed.CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder
Sambhavi Krishnamoorthy et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study
Laura N. Walti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Multipathogen-specific T cells against viral and fungal infections
Anastasia Papadopoulou et al.
BONE MARROW TRANSPLANTATION (2021)
Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA-mismatched allogeneic stem cell transplant using infusion of third-party T cells from multiple donors in addition to antivirals, rituximab, and surgery
Pietro R. Di Ciaccio et al.
TRANSPLANT INFECTIOUS DISEASE (2021)
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells
Soi C. Law et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival
M. M. Ali et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Ting-Ting Yang et al.
FRONTIERS IN ONCOLOGY (2021)
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation
Maria A. Marzolini et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant
David Jonathan Gottlieb et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities
Rama Al Hamed et al.
BONE MARROW TRANSPLANTATION (2020)
Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield
F. M. Montes de Jesus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Francesca Bonifazi et al.
BONE MARROW TRANSPLANTATION (2020)
Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes
Yuhua Ru et al.
BONE MARROW TRANSPLANTATION (2020)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Susan Prockop et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Allogeneic stem cell transplant (HSCT) for acute lymphoblastic leukaemia (ALL) using CD34 selected stem cells followed by prophylactic infusions of pathogen-specific and CD19 CAR T cells
E. Blyth et al.
CYTOTHERAPY (2020)
Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation
Julian Lindsay et al.
REVIEWS IN MEDICAL VIROLOGY (2020)
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact
Valeria Ferla et al.
FRONTIERS IN ONCOLOGY (2020)
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG
Jad Othman et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis
Maria Queralt Salas et al.
LEUKEMIA & LYMPHOMA (2020)
ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV plus PTLD) after failure of rituximab or rituximab and chemotherapy
N. Worel et al.
ANNALS OF ONCOLOGY (2020)
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation
Tania Jain et al.
LEUKEMIA & LYMPHOMA (2019)
Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources
Elizabeth M. Hellewell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation
Ayumi Fujimoto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Irene Garcia-Cadenas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk
Koen Van Besien et al.
LEUKEMIA & LYMPHOMA (2019)
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Upton D. Allen et al.
CLINICAL TRANSPLANTATION (2019)
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor
Patrick-Pascal Strunz et al.
LEUKEMIA & LYMPHOMA (2019)
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study
Seema Naik et al.
TRANSPLANT INFECTIOUS DISEASE (2019)
PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories
Ana-Iris Schiefer et al.
CANCER MEDICINE (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
Thomas Mika et al.
FRONTIERS IN MEDICINE (2019)
Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against Adv, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant
Ifigeneia Tzannou et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder
Amit Kalra et al.
CYTOTHERAPY (2018)
The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients
Neval E. Wareham et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Post-Transplantation Lymphoproliferative Disorders in Adults
Daan Dierickx et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients
Masaki Yamada et al.
PEDIATRIC TRANSPLANTATION (2018)
Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children
Fang Kuan Chiou et al.
PEDIATRIC TRANSPLANTATION (2018)
The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience
Anthea C. Peters et al.
TRANSPLANTATION (2018)
Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation
Amit Kalra et al.
CLINICAL TRANSPLANTATION (2018)
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review
M. A. AlDabbagh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Frederic Baron et al.
HAEMATOLOGICA (2017)
Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Frederic Baron et al.
HAEMATOLOGICA (2017)
Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Carlos Solano et al.
JOURNAL OF CLINICAL VIROLOGY (2017)
Viral infections in solid organ transplant recipients: novel updates and a review of the classics
Ghady Haidar et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2017)
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells
Barbara Withers et al.
BLOOD ADVANCES (2017)
Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Tania Jain et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study
A. Durrbach et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases
Jennifer A. Kanakry et al.
BLOOD (2016)
Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections
R. J. O'Reilly et al.
BONE MARROW TRANSPLANTATION (2016)
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
D. M. Burns et al.
BONE MARROW TRANSPLANTATION (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
Multicenter Evaluation of Whole-Blood Epstein-Barr Viral Load Standardization Using the WHO International Standard
Touyana Semenova et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2016)
Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients
Julio Pascual et al.
TRANSPLANT INFECTIOUS DISEASE (2016)
894895 Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy
Mihaja Raberahona et al.
TRANSPLANT INFECTIOUS DISEASE (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder
M. R. Luskin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Association of Antibody Induction Immunosuppression With Cancer After Kidney Transplantation
Erin C. Hall et al.
TRANSPLANTATION (2015)
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
J. Peccatori et al.
LEUKEMIA (2015)
Infectious mononucleosis
Henry H. Balfou et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2015)
EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era
C. P. Fox et al.
BONE MARROW TRANSPLANTATION (2014)
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
Michael Uhlin et al.
HAEMATOLOGICA (2014)
Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disorder
M. Green et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
Jennifer A. Kanakry et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen et al.
BLOOD (2013)
Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Jan Styczynski et al.
CLINICAL INFECTIOUS DISEASES (2013)
Associations Between EBV Serostatus and Organ Transplant Type in PTLD Risk: An Analysis of the SRTR National Registry Data in the United States
V. R. Dharnidharka et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT
A. Dominietto et al.
BONE MARROW TRANSPLANTATION (2012)
Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients
Marcelo Santos Sampaio et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients
Nishitha Reddy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Andrew M. Evens et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren et al.
BLOOD (2009)
Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases
J. Styczynski et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease
Hiroshi Kimura et al.
REVIEWS IN MEDICAL VIROLOGY (2008)
Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults
Etienne M. Sokal et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
Tanzina Haque et al.
BLOOD (2007)
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients
TC Lee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation
S Chakrabarti et al.
BLOOD (2003)
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
JWJ van Esser et al.
BLOOD (2002)
Share Paper
